Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Acyl-CoA synthetase 6 is required for brain docosahexaenoic acid retention and neuroprotection during aging
Regina F. Fernandez, Andrea S. Pereyra, Victoria Diaz, Emily S. Wilson, Karen A. Litwa, Jonatan Martínez-Gardeazabal, Shelley N. Jackson, J. Thomas Brenna, Brian P. Hermann, Jeffrey B. Eells, Jessica M. Ellis
Regina F. Fernandez, Andrea S. Pereyra, Victoria Diaz, Emily S. Wilson, Karen A. Litwa, Jonatan Martínez-Gardeazabal, Shelley N. Jackson, J. Thomas Brenna, Brian P. Hermann, Jeffrey B. Eells, Jessica M. Ellis
View: Text | PDF
Research Article Inflammation Metabolism

Acyl-CoA synthetase 6 is required for brain docosahexaenoic acid retention and neuroprotection during aging

  • Text
  • PDF
Abstract

The omega-3 fatty acid docosahexaenoic acid (DHA) inversely relates to neurological impairments with aging; however, limited nondietary models manipulating brain DHA have hindered a direct linkage. We discovered that loss of long-chain acyl-CoA synthetase 6 in mice (Acsl6–/–) depletes brain membrane phospholipid DHA levels, independent of diet. Here, Acsl6–/– brains contained lower DHA compared with controls across the life span. The loss of DHA- and increased arachidonate-enriched phospholipids were visualized by MALDI imaging predominantly in neuron-rich regions where single-molecule RNA in situ hybridization localized Acsl6 to neurons. ACSL6 is also astrocytic; however, we found that astrocyte-specific ACSL6 depletion did not alter membrane DHA because astrocytes express a non–DHA-preferring ACSL6 variant. Across the life span, Acsl6–/– mice exhibited hyperlocomotion, impairments in working spatial memory, and increased cholesterol biosynthesis genes. Aging caused Acsl6–/– brains to decrease the expression of membrane, bioenergetic, ribosomal, and synaptic genes and increase the expression of immune response genes. With age, the Acsl6–/– cerebellum became inflamed and gliotic. Together, our findings suggest that ACSL6 promotes membrane DHA enrichment in neurons, but not in astrocytes, and is important for neuronal DHA levels across the life span. The loss of ACSL6 impacts motor function, memory, and age-related neuroinflammation, reflecting the importance of neuronal ACSL6-mediated lipid metabolism across the life span.

Authors

Regina F. Fernandez, Andrea S. Pereyra, Victoria Diaz, Emily S. Wilson, Karen A. Litwa, Jonatan Martínez-Gardeazabal, Shelley N. Jackson, J. Thomas Brenna, Brian P. Hermann, Jeffrey B. Eells, Jessica M. Ellis

×

Figure 1

Effects of Acsl6 loss on hippocampal DHA content during aging.

Options: View larger image (or click on image) Download as PowerPoint
Effects of Acsl6 loss on hippocampal DHA content during aging.
(A) Heatm...
(A) Heatmap of PCs clustered by degree of saturation in the control and Acsl6–/– hippocampus, n = 5. Data are presented as percent of ion intensity distribution; species more than 0.5% of total are shown. (B and C) Percent of total hippocampal fatty acid content in 6-month-old control, Acsl6G–/–, and Acsl6–/– mice; n = 3–6. (D) Hippocampal immunoblot against ACSL6 and (E) cerebellar gate domain-targeted RT-PCR in control, Acsl6G–/–, and Acsl6–/– mice; n = 4. (F) Percent change of DHA from 6 to 18 months in the control and Acsl6–/– hippocampus; n = 3–6. (G) Omega-6 to omega-3 ratio. (H) Percent of omega-3 and omega-6 total fatty acids in 6- and 18-month-old control and Acsl6–/– hippocampus, n = 3–6. Data are shown as the mean ± SEM; *compared with control, &by age within genotype, #compared with Acsl6G–/–, P ≤ 0.05 (B, C, and E) by 1-way ANOVA with Tukey’s post hoc test, (G and H) by 2-way ANOVA with Sidak’s post hoc test, and (F) by 2-tailed Student’s t test.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts